SCHEMBL10292980

SCHEMBL10292980

O=C(c1cc(O)cc(O)c1)c1c[nH]c2ncc(-c3ccccc3)cc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 12/20 0.64
AAK1 Q2M2I8 1/20 0.59
SGK1 O00141 3/20 0.56
CAMKK2 Q96RR4 3/20 0.56
CDK8 P49336 1/20 0.53
TNIK Q9UKE5 1/20 0.53
PAK1 Q13153 1/20 0.53
GSK3B P49841 2/20 0.52
CDC7 O00311 1/20 0.51
PLK4 O00444 1/20 0.51
CHEK1 O14757 1/20 0.51
AURKA O14965 1/20 0.51
MAPK13 O15264 1/20 0.51
PDPK1 O15530 1/20 0.51
DYRK3 O43781 1/20 0.51
ROCK2 O75116 1/20 0.51
RPS6KA5 O75582 1/20 0.51
PRKD3 O94806 1/20 0.51
PAK4 O96013 1/20 0.51
CHEK2 O96017 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL857422 0.90 AXL (0.61) AXLAAK1SGK1CAMKK2CDK8
SCHEMBL10293346 0.88 BRD4 (0.56) AXLAAK1PAK1NTRK1CDK2
SCHEMBL1516774 0.85 AAK1 (0.66) AXLAAK1SGK1CAMKK2CDK8
SCHEMBL415002 0.83 AXL (0.69) AXLAAK1SGK1CAMKK2GSK3B
SCHEMBL878650 0.82 TNIK (0.54) AXLAAK1CAMKK2TNIKNTRK1
SCHEMBL857046 0.81 AXL (0.59) AXLAAK1SGK1CAMKK2CDK8
SCHEMBL857630 0.81 AXL (0.58) AXLAAK1SGK1CAMKK2CDK8
SCHEMBL24296622 0.80 AXL (0.76) AXLAAK1SGK1CAMKK2CDK8
SCHEMBL20584650 0.80 AXL (0.71) AXLAAK1SGK1CAMKK2CDK8
SCHEMBL414820 0.80 AXL (0.58) AXLAAK1SGK1CAMKK2CDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143271-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2012-03-27 US disclosed
US-20100256365-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256365-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 AXL 1354/4885AAK1 335/4885SGK1 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.